[1]古丽胡马尔·艾尼瓦尔,吐比克孜·依比力,苏比努尔·买买提,等.多囊卵巢综合征患者血清IL-36α，CTRP6水平表达与临床诊断价值研究[J].现代检验医学杂志,2024,39(06):119-123.[doi:10.3969/j.issn.1671-7414.2024.06.020]
　GULIHUMAER Ainiwaer,TUBIKEIZ ribili,SUBINUER Maimaiti,et al.Study on the Expression of Serum IL-36α and CTRP6 in Patients with Polycystic Ovary Syndrome and Their Clinical Diagnostic Value[J].Journal of Modern Laboratory Medicine,2024,39(06):119-123.[doi:10.3969/j.issn.1671-7414.2024.06.020]
点击复制

多囊卵巢综合征患者血清IL-36α，CTRP6水平表达与临床诊断价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年06期
页码:
119-123
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Study on the Expression of Serum IL-36α and CTRP6 in Patients with Polycystic Ovary Syndrome and Their Clinical Diagnostic Value
文章编号:
1671-7414（2024）06-119-05
作者:
古丽胡马尔·艾尼瓦尔; 吐比克孜·依比力; 苏比努尔·买买提; 尼比热·阿布都瓦依提; 易金玲
（新疆医科大学第五附属医院妇科，乌鲁木齐 830011）
Author(s):
GULIHUMAER Ainiwaer;  TUBIKEIZ ribili;  SUBINUER Maimaiti;  NIBIRE Abuduwayiti;  YI Jinling
（Department of Gynaecology, the Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China）
关键词:
多囊卵巢综合征; 白细胞介素-36α; C1q/ 肿瘤坏死因子相关蛋白6
分类号:
R711.75；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.06.020
文献标志码:
A
摘要:
目的 研究多囊卵巢综合征（polycystic ovary syndrome，PCOS）患者血清白细胞介素-36α（interleukin-36α，IL-36α）、C1q/ 肿瘤坏死因子相关蛋白6（C1q/tumor necrosis factor-related protein 6，CTRP6）水平表达及临床诊断价值研究。方法 选取2019 年4 月～ 2022 年4 月新疆医科大学第五附属医院就诊的98 例PCOS 患者（PCOS 组），以70 例同期体检的健康女性为对照（对照组）。酶联免疫吸附实验（ELISA）检测两组血清IL-36α，CTRP6 表达。Pearson 相关分析血清IL-36α，CTRP6 水平与临床指标的相关性。多因素Logistic 回归分析影响PCOS 发生的因素。受试者工作特征（ROC）曲线评价血清IL-36α，CTRP6 及联合检测对PCOS 的诊断效能。结果 PCOS 组血清CTRP6（18.25±3.67μg/L）、空腹血糖（5.71±0.49nmol/L）、空腹胰岛素（18.96±2.68mIU/L）、稳态模型胰岛素抵抗指数（HOMA-IR）（4.72±0.46）、黄体生成素（6.17±1.44Iu/L）、睾酮（1.32±0.42nmol/L）、卵巢数目（17.86±5.20个）和卵巢体积（9.29±2.14cm3）高于对照组（5.14±1.28μg/L，4.76±0.54mmol/L，8.63±1.65mIU/L，1.83±0.33,4.92±1.39IU/L，0.86±0.28nmol/L，6.76±1.94 个，5.26±1.31cm3），而血清IL-36α（0.67±0.13ng/L）、卵泡刺激素（4.27±1.33IU/L）低于对照组（2.11±0.38ng/L，5.42±1.67IU/L），差异具有统计学意义（t/χ2=4.962 ～ 44.934，均P＜ 0.05）。1 型、2 型、3 型和4 型PCOS 患者血清IL-36α（0.87±0.15ng/L，0.70±0.12ng/L，0.51±0.11ng/L，0.42±0.10ng/L）水平依次降低，而CTRP6（14.07±3.35μg/L，17.66±3.97μg/L，21.16±3.67μg/L，24.08±3.53μg/L）水平依次升高，差异具有统计学意义（F=61.281，33.854，均P ＜ 0.05）。血清IL-36α 与卵巢数目、卵巢体积、空腹胰岛素、HOMA-IR 呈负相关（r=-0.661，-0.621，-0.554，-0.671，均P<0.05）。血清CTRP6 与卵巢数目、卵巢体积、空腹胰岛素、HOMA-IR 呈正相关（r=0.625，0.631，0.537，0.738，均P<0.05）。CTRP6（OR=1.327，95%CI：1.104 ～ 1.596）是影响PCOS 发生的独立危险因素，IL-36α（OR=0.707，95%CI：0.547 ～ 0.914）是保护因素。血清IL-36α，CTRP6联合检测诊断PCOS 的曲线下面积（95%CI）为0.933(0.872 ～ 0.969)，大于单一指标检测的0.870（0.821 ～ 0.926）和0.898(0.854 ～ 0.940)，差异具有统计学意义(Z=4.258，4.119，均P ＜ 0.05)。结论 PCOS 患者血清IL-36α 降低，CTRP6 水平升高，与PCOS 病情程度有关，两者联合检测对PCOS 具有较高的诊断价值。
Abstract:
Objective To study the serum expression of interleukin-36α (IL-36α), C1q/tumor necrosis factor-related protein 6 (CTRP6) levels in patients with polycystic ovary syndrome (PCOS) and their diagnostic value. Methods A total of 98 PCOS patients diagnosed and treated in the Fifth Affiliated Hospital of Xinjiang Medical University from April 2019 to April 2022 were taken as the PCOS group, and 70 healthy women were taken as the control group. Enzyme-linked immunosorbent assay was applied to detect serum IL-36 α and CTRP6 level expression. The correlation between the expression of serum IL-36 α, CTRP6 levels and clinical indicators was analyzed by Pearson correlation analysis. Multivariate logistic regression analysis was used to analyze factors affecting the occurrence of PCOS. Receiver operating characteristic curve was used to evaluate the diagnostic efficacy of serum IL-36α, CTRP6 and combination in PCOS. Results Serum CTRP6 (18.25±3.67μg/L),FPG(5.71±0.49nmol/L), FINS(18.96±2.68mIU/L), HOMA-IR(4.72±0.46), LH(6.17±1.44IU/L), T(1.32±0.42nmol/L), ovarian number(17.86±5.20) and ovarian volume(9.29±2.14cm3) in the PCOS group were higher, while serum IL-36 α (0.67±0.13ng/L) and FSH(（4.27±1.33IU/L) were lower compared with those in the control group(5.14±1.28μg/L， 4.76±0.54mmol/L，8.63±1.65mIU/L，1.83±0.33, 4.92±1.39IU/L，0.86±0.28nmol/L，6.76±1.94 个，5.26±1.31cm3, 2.11±0.38ng/L，5.42±1.67IU/L), with significant differences (t/χ2=4.962 ～44.934, all P<0.05). Serum IL-36α (0.87 ± 0.15ng/ L, 0.70 ± 0.12ng/L, 0.51 ± 0.11ng/L, 0.42 ± 0.10ng/L) levels in patients with type 1, type 2, type 3, and type 4 PCOS were decreased sequentially, while CTRP6 (14.07 ± 3.35 μg/L, 17.66 ± 3.97 μg/L, 21.16 ± 3.67 μg/L, 24.08 ± 3.53 μg/L) were increased sequentially, with significant differences (F=61.281, 33.854, all P<0.05). There was a negative correlation between serum IL-36 α and ovarian number, ovarian volume, FINS and HOMA-IR (r=-0.661, -0.621, -0.554, -0.671, all P<0.05). Serum CTRP6 was positively correlated with ovarian number, ovarian volume, FINS and HOMA-IR (r=0.625, 0.631, 0.537, 0.738, all P<0.05). CTRP6 (OR=1.327, 95%CI:1.104 ～ 1.596) was an independent risk factor affecting the occurrence of PCOS, while IL-36 α (OR=0.707, 95%CI: 0.547 ～ 0.914) was a protective factor. The area under the curve (95% CI) of combination of IL-36 α and CTRP6 for the diagnosis of PCOS was 0.933 (0.872~0.969), which was greater than that of IL-36 α, CTRP6 alone [0.870 (0.821~0.926), 0.898 (0.854~0.940)], with significant differences (Z=4.258, 4.119, all P<0.05). Conclusion The decrease of serum IL-36α and the increase of CTRP6 in PCOS patients are related to the severity of PCOS, and the combined detection of the two may have high diagnostic value for PCOS.

参考文献/References:

[1] SADEGHI H M, ADELI I, CALINA D, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis,management, and drug repurposing[J]. International Journal of Molecular Sciences, 2022, 23(2): 583.
[2] ELIAS M, ZHAO Shuai, LE H T, et al. IL-36 in chronic inflammation and fibrosis - bridging the gap?[J]. Journal of Clinical Investigation, 2021, 131(2): e144336.
[3] CONTI P, PREGLIASCO F E, BELLOMO R G, et al. Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: a novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra[J]. International Journal of Molecular Sciences,2021, 22(15): 8076.
[4] GIANNOUDAKI E, HERNANDEZ-SANTANA Y E,MULFAUL K, et al. Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction[J]. Nature Communications,2019, 10(1): 4003.
[5] LAHAV R, HAIM Y, BHANDARKAR N S, et al. CTRP6 rapidly responds to acute nutritional changes, regulating adipose tissue expansion and inflammation in mice[J]. American Journal of Physiology-Endocrinology and Metabolism, 2021, 321(5): E702-E713.
[6] HU Bo, QIAN Xiaolan, QIAN Ping, et al. Advances in the functions of CTRP6 in the development and progression of the malignancy[J]. Frontiers in Genetics,2022, 13: 985077.
[7] XIE Yuhong, XIAO Yi, HUANG Qiong, et al. Role of the CTRP6/AMPK pathway in kidney fibrosis through the promotion of fatty acid oxidation[J]. European Journal of Pharmacology, 2021, 892: 173755.
[8] 中国医师协会内分泌代谢科医师分会.多囊卵巢综合征诊治内分泌专家共识[J].中华内分泌代谢杂志,2018, 34(1): 1-7. Chinese Endocrinologist Association, Chinese Medical Doctor Association. Endocrinologist consensus on the management of polycystic ovary syndrome[J]. Chinese Journal of Endocrinology and Metabolism, 2018, 34(1): 1-7.
[9] TEEDE H J, MISSO M L, COSTELLO M F, et al. Erratum. recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Human Reproduction,2019, 34(2): 388.
[10] 朱琳, 林延润, 杨发达, 等.PCOS 患者胰岛素释放试验峰值后移与胰岛素分泌总量及敏感性的特征分析[J]. 现代检验医学杂志, 2022, 37(5): 154-158. ZHU Lin, LIN Yanrun, YANG Fada, et al. Analysis of the relationship between the peak shift of insulin release test and total insulin secretion and sensitivity in patients with PCOS[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 154-158.
[11] POPOVIC M, SARTORIUS G, CHRIST-CRAIN M. Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?[J]. Seminars in Immunopathology, 2019,41(4): 447-459.
[12] BARBIER L, FERHAT M, SALAM? E, et al. Interleukin-1 family cytokines: keystones in liver inflammatory diseases[J]. Frontiers in Immunology,2019, 10: 2014.
[13] EROGLU S, CAKMAKLIOGULLARI E K. Decreased serum profile of the interleukin-36α in polycystic ovary syndrome[J]. Taiwanese Journal of Obstetrics Gynecology, 2021, 60(6): 1018-1022.
[14] FRUHBECK G, GOMEZ A J, RAMIREZ B, et al. Increased levels of interleukin-36 in obesity and type 2 diabetes fuel adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages[J]. Frontiers in Immunology, 2022, 13(5): 8321-8335.
[15] SADEGHI A, FADAEI R, MORADI N, et al. Circulating levels of C1q/TNF-α-related protein 6 (CTRP6) in polycystic ovary syndrome[J]. IUBMB Life, 2020, 72(7): 1449-1459.
[16] LEI Xia, SELDIN M M, LITTLE H C, et al. C1q/TNFrelated protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance[J]. Journal of Biological Chemistry, 2017, 292(36): 14836-14850.
[17] GAO Yue, CHEN Jiao, JI Rui, et al. USP25 regulates the proliferation and apoptosis of ovarian granulosa cells in polycystic ovary syndrome by modulating the PI3K/AKT pathway via deubiquitinating PTEN[J]. Frontiers in Cell and Developmental Biology, 2021, 9: 779718.
[18] DONG Xunzhong, HU Hejie, FANG Zhengdong, et al. CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration[J]. Biomedicine & Pharmacotherapy, 2018, 103: 844-850.
[19] SHIN J, TOYODA S, NISHITANI S, et al. SARSCoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1[J]. Metabolism, 2022, 133: 155236.

相似文献/References:

[1]李晓丽,赵　莉,曹阳阳,等.多囊卵巢综合征患者血清肌联素水平表达与多种生化代谢指标的相关性分析[J].现代检验医学杂志,2020,35(06):111.[doi:doi:10.3969/j.issn.1671-7414.2020.06.027]
　LI Xiao-li,ZHAO Li,CAO Yang-yang,et al.Correlation Analysis between Expression of Serum Myonectin and VariousBiochemical and Metabolic Indexes in Patients with Polycystic Ovary Syndrome[J].Journal of Modern Laboratory Medicine,2020,35(06):111.[doi:doi:10.3969/j.issn.1671-7414.2020.06.027]
[2]钟社兰,李功娟,樊阳阳,等.多囊卵巢综合征患者血清中Neudesin水平及其与多项生理生化指标的相关性分析[J].现代检验医学杂志,2021,36(02):98.[doi:doi:10.3969/j.issn.1671-7414.2021.02.023]
　ZHONG She-lan,LI Gong-juan,FAN Yang-yang,et al.Correlation Analysis of Serum Neudesin Level and Multiple Physiological and Biochemical Indexes in Patients with Polycystic Ovarian Syndrome[J].Journal of Modern Laboratory Medicine,2021,36(06):98.[doi:doi:10.3969/j.issn.1671-7414.2021.02.023]
[3]曹阳阳,樊阳阳,宋秀英,等.多囊卵巢综合征患者血清镍纹样蛋白水平检测的临床意义及与实验室指标的相关性研究[J].现代检验医学杂志,2021,36(02):111.[doi:doi:10.3969/j.issn.1671-7414.2021.02.026]
　CAO Yang-yang,FAN Yang-yang,SONG Xiu-ying,et al.Clinical Significance of Serum Metrnl Protein Level Detection in Patients with Polycystic Ovary Syndrome and Its Correlation with Laboratory Indexes[J].Journal of Modern Laboratory Medicine,2021,36(06):111.[doi:doi:10.3969/j.issn.1671-7414.2021.02.026]
[4]宋秀英,樊阳阳,赵　莉,等.多囊卵巢综合征患者血清 Spexin 水平表达及其与多项生理生化指标的相关性分析[J].现代检验医学杂志,2021,36(03):80.[doi:10.3969/j.issn.1671-7414.2021.03.018]
　SONG Xiu-ying,ZHAO Li,CAO Yang-yang,et al.Expression of Serum Spexin in Patients with Polycystic Ovary Syndrome andIts Correlation with Multiple Physiological and Biochemical Indexes[J].Journal of Modern Laboratory Medicine,2021,36(06):80.[doi:10.3969/j.issn.1671-7414.2021.03.018]
[5]林延润a,邱伟全b,彭学博,等.多囊卵巢综合征患者血清性激素水平与胰岛素释放峰值后移的相关性研究[J].现代检验医学杂志,2021,36(06):143.[doi:10.3969/j.issn.1671-7414.2021.06.031]
　LIN Yan-run,PENG Xue-bo,QIU Wei-quan,et al.Study on the Relationship between Serum Sex Hormone Level and Insulin Release Peak Shift in Patients with Polycystic Ovary Syndrome[J].Journal of Modern Laboratory Medicine,2021,36(06):143.[doi:10.3969/j.issn.1671-7414.2021.06.031]
[6]朱 琳,林延润,杨发达,等.PCOS 患者胰岛素释放试验峰值后移与胰岛素分泌总量及敏感性的特征分析[J].现代检验医学杂志,2022,37(05):154.[doi:10.3969/j.issn.1671-7414.2022.05.030]
　ZHU Lin,LIN Yan-run,YANG Fa-da,et al.Analysis of the Relationship between the Peak Shift of Insulin Release Test and Total Insulin Secretion and Sensitivity in Patients with PCOS[J].Journal of Modern Laboratory Medicine,2022,37(06):154.[doi:10.3969/j.issn.1671-7414.2022.05.030]
[7]鲁 霞,曹党恩,李晓兰.多囊卵巢综合征患者血清GnSAF, Irisin, Copeptin 表达水平及其与妊娠结局的相关性研究[J].现代检验医学杂志,2022,37(06):34.[doi:10.3969/j.issn.1671-7414.2022.06.007]
　LU Xia,CAO Dang-en,LI Xiao-lan.Changes of Serum GnSAF, Irisin and Copeptin Levels in Patients with Polycystic Ovary Syndrome and Their Relationship with Pregnancy Outcomes[J].Journal of Modern Laboratory Medicine,2022,37(06):34.[doi:10.3969/j.issn.1671-7414.2022.06.007]
[8]朱 琳,陈跃瑜,林延润,等.PCOS 患者MTHFR C677T 基因多态性与胰岛素峰值后移的相关性研究[J].现代检验医学杂志,2023,38(06):54.[doi:10.3969/j.issn.1671-7414.2023.06.010]
　ZHU Lin,CHEN Yueyu,LIN Yanrun,et al.Relationship between MTHFR C677T Polymorphism and Insulin Peak Shift in Patients with PCOS[J].Journal of Modern Laboratory Medicine,2023,38(06):54.[doi:10.3969/j.issn.1671-7414.2023.06.010]

备注/Memo

备注/Memo:
基金项目：新疆维吾尔自治区科技支疆计划项目（2020E02129）。
作者简介： 古丽胡马尔·艾尼瓦尔（1995-），女，硕士研究生，住院医师，研究方向：早发性卵巢功能不全、多囊卵巢综合征，E-mail：Humar331@163.com。
通讯作者： 易金玲（1976-），女，博士，主任医师，研究方向：早发性卵巢功能不全、多囊卵巢综合征，E-mail：1441269692@qq.com。
更新日期/Last Update: 2024-11-15